fda warning bpc 157 peptide unapproved bpc-157 FDA Compliance for Peptide Therapy and BPC-157 – Holt Law EVEXIAS Life Sciences filing lawsuit

The original characterization by the Sikiri group framed the larger parent protein in human gastric juice as a protective factor for the gastrointestinal mucosa, with body protection compound (BPC) referring to that broader protective role

Thousands of anecdotal reports support its safety for: Subcutaneous and intramuscular injection Oral use for GI issues Short-term protocols (26 weeks) Still, because of its unregulated status, quality and dosing inconsistencies in peptide sourcing pose additional risks

Independently tested and certified for purity

Animal studies using BPC-157 on transected tendons show restored biomechanical properties approaching pre-injury levels

This potent combination works synergistically to reduce oxidative stress, support cellular health, and boost your body's natural defense mechanisms